Cyclin D1 and Lung Cancer Prognosis
Author Information
Author(s): Keum J S, Kong G, Yang S C, Shin D H, Park S S, Lee J H, Lee J D
Primary Institution: Department of Pathology, School of Medicine, Sungkyunkwan University
Hypothesis
Cyclin D1 overexpression is correlated with poor prognosis in resectable non-small cell lung cancer patients.
Conclusion
Cyclin D1 overexpression is linked to shorter overall survival in non-small cell lung cancer patients.
Supporting Evidence
- Cyclin D1 overexpression was found in 34.8% of the patients.
- Patients with lymph node metastasis had a higher rate of cyclin D1 overexpression (50.0%).
- Patients with advanced pathological stages showed significant cyclin D1 overexpression.
- Cyclin D1-positive patients had a shorter overall survival of 24.0 months compared to 50.1 months for negative patients.
Takeaway
If a cancer patient has too much cyclin D1, it might mean their cancer is worse and they might not live as long.
Methodology
Immunohistochemical examination of formalin-fixed and paraffin-embedded tumor tissues from NSCLC patients.
Participant Demographics
Patients with resectable non-small cell lung cancer between stages I and IIIa.
Statistical Information
P-Value
0.002, 0.048, 0.0299, 0.0066
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website